WO1997039139A1 - A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer - Google Patents
A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer Download PDFInfo
- Publication number
- WO1997039139A1 WO1997039139A1 PCT/US1997/006497 US9706497W WO9739139A1 WO 1997039139 A1 WO1997039139 A1 WO 1997039139A1 US 9706497 W US9706497 W US 9706497W WO 9739139 A1 WO9739139 A1 WO 9739139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- prostate cancer
- psa
- prostate
- monitoring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- RT-PCR reverse-transcriptase PCR
- cDNA complementary DNA
- RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.
- PSA Prostate-specific antigen
- RT-PCR of mRNA encoding for PSA has been used in the identification of prostate cancer cells.
- Deguchi et al. detected PSA mRNA in regional lymph nodes from patients with prostate cancer which had metastasized to the lymphatic system. Cancer Res. 1993, 53:5350-4.
- RT-PCR methods for detection of prostate cancer cells in the general circulation of patients with advanced prostate cancer have also been disclosed. Moreno et al. Cancer Res. 1992, 53:6110-2; Jaakkola et al. Clin. Chem. 1995, 41(2): 182- 186.
- patients with early prostate cancer and/or well differentiated or localized disease were found negative for PSA mRNA by PCR. Accordingly, it was concluded that RT-PCR for PSA mRNA would not be a useful tool for either the diagnosis or monitoring of prostate cancer. Diamandis, E.P. and Yu, H. Clin. Chem. 1995, 41(2): 177-179.
- An object of the present invention is to provide primers for use in an RT-PCR method for the detection of prostatic specific antigen for the monitoring and diagnosis of patients with prostate cancer.
- Figure 1 provides the human DNA for prostate specific antigen (PSA) (SEQ ID NOS: 1, 8, 9 and 10). Introns are abbreviated for clarity. Exons are indicated in bold. Primers previously disclosed in the art are indicated by underlining. The primers of the present invention, namely DR PSA-up (SEQ ED NO: 2), DR PSA- Down (SEQ ID NO: 3) and DR 12 mer (SEQ ID NO: 4), are indicated by underlined italics in a larger font size.
- PSA prostate specific antigen
- a new method for the detection of prostate specific antigen by reverse- transcriptase polymerase chain reaction has been developed which can be used in the monitoring of prostate cancer in a patient.
- Primers which are used in the method of the present invention include DR PSA-Up: 5'-GTTGTCITCCTCACCCrGTCCG-3' (SEQ LO NO: 2), DR PSA-Down: S'-TCCAGCACACAGCATGAACTTG-S' (SEQ LD NO: 3), and DR 12 mer: 5'-GAATCACCCGAG-3' (SEQ LD NO: 4).
- the method of the present invention comprises isolation and washing of buffy coat cells, isolation of total RNA from buffy coat cells, reverse transcription (RT) reaction for PSA, PCR for PSA, and detection of the absence or presence of PSA product on a DNA sequencer.
- the method may further comprise RT reaction and PCR for a housekeeping gene Beta-2-microglobulin (B2G: Israeli et al. Cancer Research 1994 54:6306-6310) to momtor quality of the isolated RNA.
- B2G Israeli et al. Cancer Research 1994 54:6306-6310
- Vacutainer Systems Cat. #362761 Sodium Citrate anticoagulant, 8 ml draw, San Jose, CA are used to collect blood samples from patients suspected of having prostate cancer. These samples are then centrifuged in accordance with the manufacturer's instructions to separate the buffy coat from other blood components. Buffy coat cells are then washed with PBS and pelleted by centrifugation. The pelleted cells are taken up in a cell lysis buffer. Cells are homogenized by passage over a Qiagen QIA shredder microspin column. The run-through is then passed over a Qiagen RNeasy column to bind RNA. The sample is washed to remove DNA and other components, and the RNA is eluted with DEPC-treated water.
- the eluted sample RNA is then used as the substrate in the RT reactions.
- the RT reaction primer for PSA reactions is DR 12 mer (SEQ ID NO: 4) which is specific for the PSA target.
- An aliquot of the RT reaction is then used for the PCR reaction for PSA, using primers DR PSA Up (SEQ ID NO: 2) and DR PSA Down (SEQ ID NO: 3).
- the method further comprises RT reaction and PCR for B2G to monitor quality of the isolated RNA
- the RT reaction primer is 5'-AGCTTTGAGTGC-3' (SEQ ED NO: 5) and the PCR reaction primers are 5'-AGCAGAGAATGGAAAGTCAAA-3' (SEQ ED NO: 6) and 5 -TGT TGATGT TGGATAAGAGAAT-3 1 (SEQ ID NO: 7).
- the sizes of the products from each reaction for each patient are compared on the ABI 373 DNA Analyzer with the ABI 672 GENESCAN software.
- BPH samples included patients diagnosed with BPH but not cancer. Prostate cancer status was provided by the patient's physician.
- Samples from patients having stage B cancer, or organ-confined cancer, which is not metastatic were nonreactive in the method of the present invention. Further, stable patients, meaning those with metastases in the past but no further progression in 5 or more years, who are considered cured, were also nonreactive. Recent studies indicate that circulating prostate cells can also result from prostatectomy operations. Oefelein et al. J. Urol. 1996 155:238-242. If cancerous, these circulating cells caused by the surgery could result in metastases. The method of the present invention can be used in monitoring these surgical procedures to ensure that a patient is nonreactive prior to surgery as well as after the surgery.
- kits for monitoring of progression of prostate cancer which comprise the DR PSA-Up (SEQ ED NO: 2), DR PSA-Down (SEQ ID NO: 3), and DR 12 mer (SEQ ID NO: 4) primers.
- these kits also comprise primers for RT and PCR detection of B2G such as SEQ ED NOs: 5, 6 and 7.
- kits of the present invention may comprise tubes for collection of blood samples which are capable of separating the buffy coat from other blood components such as Vacutainer Cell Preparation Tubes.
- Kits of the present invention may also comprise a means for isolating RNA.
- the kit may comprise a cell lysis buffer, Qiagen QIA shredder microspin columns (Cat. #79655) for cell homogenization and Qiagen RNeasy columns (Cat. #74106) for binding of the RNA.
- the kits may also contain any of the following reagents including, but not limited to, Beta-Mercaptoethanol (BME), Diethyl Pyrocarbonate (DEPC), Superscript II RNase H- Reverse Transcriptase (Gibco BRL, Gaithersburg, MD), ethanol (200 Proof), 100 mM dNTPs, AmpliTaq DNA Polymerase (Perkin Elmer Cat. #N808-0153), 6% (6% T, 5%C) denaturing acrylamide gel Gibco/BRL 6% Sequencing Solution (Gel-Mix 6; Cat. #5543UA), 10 % ammonium persulfate,
- Denaturing loading buffer containing Blue dextran (50 mg/ml) and 200 ml formamide and 20 ml 100 mM EDTA, IX TBE for Sequencer Gibco/BRL UltraPure Gel-Mix running mate (Cat. #15546-013) and Brij 35 (Sigma Chemical Co. St. Louis, MO, Cat. #430AG-6). Standard and controls may also be provided in the kits of the present invention. Examples include, but are not limited to Genescan ROX-2500 standard (Perkin Elmer/ABI Cat.
- RNA from ATCC cell lines CRL-1435 PC-3 prostate adenocarcinoma, human
- HTB-22 MCF7 breast adenocarcinoma, pleural effusion, human
- RNA from ATCC cell line CRL-1740 LNCaP metalastatic prostate adenocarcinoma, human
- Reagents are prepared in essentially RNAse-free, sterile, disposable plasticware, in glassware baked at 180°C for at least 8 hours, or in polypropylene plasticware rinsed with chloroform.
- Solutions used for RNA and reverse transcription work are prepared using RNAse-free glassware, autoclaved water, and chemicals reserved for RNA work handled with baked spatulas. Water for solutions is treated with 0.1% DEPC for at least 12 hours at 37°C and then heated to 100°C for 15 minutes or autoclaved for 15 minutes at 15 lb/sq. inch on liquid cycle.
- Phosphate buffered saline (PBS) used in this method is prepared by dissolving 8 grams of NaCl, 0.2 grams of KCl, 1.44 grams of Na.HPO 4 , and 0.24 grams of KH-PO 4 in 800 ml of distilled ILG The pH of the buffer is adjusted to 7.4 with HCl. The volume is then adjusted to 1 liter with H.O. Prior to use, the buffer is sterilized by autoclaving for 20 minutes at 15 lb/sq. inch on liquid cycle and stored at room temperature. Lysis Buffer (BME) is prepared from 100 ⁇ l of BME per 10 ml of QIAGEN
- Wash Buffer RPE is prepared for use by adding 4 volumes of 96-100% ethanol to the concentrate supplied by Qiagen.
- Blood samples are obtained in Vacutainer CPT tubes with sodium citrate. The samples are then centrifuged at room temperature (20 - 25°C) in a horizontal swing-out head rotor at 1500 to 1800 RCF (Relative Centrifugal Force) for 30 minutes. After centrifugation, the buffy coat appears as a whitish layer just under the plasma layer. Approximately half of the plasma is aspirated without disturbing the cell layer. The cell layer is then collected with a sterile pipette and transferred to a 15 ml conical centrifuge tube.
- RCF Relative Centrifugal Force
- Example 3 RNA Isolation The cells/Lysis Buffer/BME suspension is pipetted directly onto a QIAGEN
- Wash Buffer RPE 500 ⁇ l is pipetted onto the spin column and centrifuge as above. The flowthrough is discarded. A second aliquot of Wash Buffer RPE is pipetted onto the spin column and centrifuged for 2 minutes at full speed to dry the RNeasy spin column. This 2 minute spin assures that no residual ethanol will be carried over during elution. The spin column is then transferred to a new 1.5 ml collection tube and the sample RNA is eluted with 50 ⁇ l of DEPC-treated water pipetted directly onto the spin column membrane followed by centrifugation for 60 seconds at 8000 x g. Sample RNA may be used immediately in the RT reaction, or stored at -70°C until further use.
- Example 4 Determining the RNA concentration
- RNA concentration in each sample is determined by UV spectrophotometry.
- the baseline absorbance of 75 ⁇ l of distilled water is first determined at 260, 280, and 320 nm.
- a five microliter sample of RNA is then added and mixed.
- the sample absorbance is then determined at 260, 280, and 320 nm.
- the neat RNA concentration is calculated by: a) subtracting the A320 from the A260 to obtain the absorbance due to RNA; b) multiplying by the dilution factor (80 ⁇ /5 ⁇ l); and c) multiplying by the conversion factor (0.04 mg/ ml).
- Example 5 Sample Reverse Transcription
- Two microliters of 50 ⁇ M PSA RT primer (SEQ ED NO: 4) are pipetted into each PCR reaction tubes.
- Two microliters of 50 ⁇ M B2G RT primer (SEQ ID NO: 5) are pipetted into separate PCR reaction tubes. Tubes may be prepared in advance and stored at -20°C. RT Reaction Mix is prepared just prior to use in the following manner: The number of sample reactions (PSA and B2G) to be run is first determined as variable X.
- B2G PCR Reaction Mix is prepared in the following manner: The number of B2G sample reactions to be run is determined as variable X. The following volumes of reagents are then mixed: 33.15(X+1) ⁇ l H j O; 4(X+1) ⁇ l 10X PCR Buffer JJ; (X+l) ⁇ l 20 mM dNTP; 0.8(X+1) ⁇ l 25 mM MgCL; 0.8(X+1) ⁇ l B2G primers (SEQ ED NOs: 6 and 7); and 0.25(X+1) ⁇ l Taq enzyme.
- RNA sample Two tubes per RNA sample are prepared, one tube for each reaction: PSA and B2G. Forty microliters of the appropriate reaction mixture are pipetted into each of the tubes. Ten microliters of the respective sample RNA or control RNA Reverse Transcription reaction are pipetted into each tube. For the negative (reaction) control, 10 ml of water are used. The tubes are spun for 10 seconds in an Eppendorf microcentrifuge to ensure all liquid is mixed together at the bottom of the tubes. The tubes are then placed in the Perkin Elmer 9600 Thermocycler and cycled as follows:
- Example 7 Sample Detection Two 6 cm well-to-read plates (one notched, one plain) are prepared for use in the following manner. Both sides of each plate are rinsed with distilled water. One side only of each plate is then selected as the inside (gel side) of the plate. This inside is then rinsed with methanol followed by 0.5% Brij. The methanol rinse is then repeated until the plates are streak free. Spacers are then placed on the edge of the plain plate, parallel to the short side of the plates. The notched plate is placed on top of the plain plate, with the insides of the plates facing each other. The plates are then stood on their bottom edge and the spacers lined up so they are level with the bottom and sides of the gel. They are gently laid down flat with the plain plate on the bottom and clamped with 6 binder clips.
- the gel is prerun for 5 minutes at 28 watts.
- Two microliters of PCR reaction are pipetted into a 0.2 ml thin-walled PCR reaction tube.
- Denaturing sample buffer (2X; 2.5 ml) and 0.3 ml of Genescan ROX-2500 standard are then added.
- the tubes are placed in a PE 9600 Thermocycler and run at 94 °C for 10 minutes.
- the thermal cycler is set to PAUSE and each tube is placed on ice.
- Four microliters of cooled sample are then loaded onto the gel.
- the ABI sequencer is set to run for 3.5 hours at 28 watts, 600 volts, 40 milliamps and the Genescan data collection to collect for 3 hours.
- TELECOMMUNICATION INFORMATION (A) TELEPHONE: 610-270-5219 (B) TELEFAX: 610-270-5090
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09537395A JP2000510331A (en) | 1996-04-16 | 1997-04-16 | Method for detecting prostate-specific antigen used in monitor observation and diagnosis of prostate cancer |
AU26761/97A AU2676197A (en) | 1996-04-16 | 1997-04-16 | A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer |
EP97918724A EP0904397A4 (en) | 1996-04-16 | 1997-04-16 | A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1576596P | 1996-04-16 | 1996-04-16 | |
US60/015,765 | 1996-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039139A1 true WO1997039139A1 (en) | 1997-10-23 |
Family
ID=21773475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/006497 WO1997039139A1 (en) | 1996-04-16 | 1997-04-16 | A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0904397A4 (en) |
JP (1) | JP2000510331A (en) |
AU (1) | AU2676197A (en) |
WO (1) | WO1997039139A1 (en) |
ZA (1) | ZA973231B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009691A2 (en) * | 1998-08-10 | 2000-02-24 | Urogenesys, Inc. | Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
WO2000044940A2 (en) * | 1999-01-28 | 2000-08-03 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2004073657A2 (en) * | 2003-02-19 | 2004-09-02 | Protein Design Labs, Inc. | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
AU2008246270B2 (en) * | 1998-08-10 | 2012-02-02 | Agensys, Inc. | BPC-1:a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506106A (en) * | 1992-10-29 | 1996-04-09 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU662906B2 (en) * | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
-
1997
- 1997-04-16 AU AU26761/97A patent/AU2676197A/en not_active Abandoned
- 1997-04-16 JP JP09537395A patent/JP2000510331A/en active Pending
- 1997-04-16 ZA ZA9703231A patent/ZA973231B/en unknown
- 1997-04-16 EP EP97918724A patent/EP0904397A4/en not_active Withdrawn
- 1997-04-16 WO PCT/US1997/006497 patent/WO1997039139A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506106A (en) * | 1992-10-29 | 1996-04-09 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
Non-Patent Citations (4)
Title |
---|
BIOCHEMICA ET BIOPHYSICA ACTA, August 1993, Volume 1174, Number 2, GAUTHIER E.R., "Characterization of Rhesus Monkey Prostate Specific Antigen cDNA", pages 207-210. * |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, February 1989, Volume 159, Number 1, RIEGMAN P.H.J. et al., "Characterization of the Prostate-Specific Antigen Gene: a Novel Human Kallikrein-Like Gene", pages 95-102. * |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, June 1989, Volume 161, Number 3, LUNDWALL A., "Characterization of the Gene for Prostate-Specific Antigen, a Human Glandular Kallikrein", pages 1151-1159. * |
See also references of EP0904397A4 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009691A2 (en) * | 1998-08-10 | 2000-02-24 | Urogenesys, Inc. | Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
WO2000009691A3 (en) * | 1998-08-10 | 2000-05-11 | Urogenesys Inc | Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
AU2008246270B2 (en) * | 1998-08-10 | 2012-02-02 | Agensys, Inc. | BPC-1:a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
US8003758B2 (en) | 1998-08-10 | 2011-08-23 | Agensys, Inc. | BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
US6277972B1 (en) | 1998-08-10 | 2001-08-21 | Urogenesys, Inc. | BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
US7785811B2 (en) | 1998-08-10 | 2010-08-31 | Agensys, Inc. | BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
US7267956B2 (en) | 1999-01-28 | 2007-09-11 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
US6811985B2 (en) | 1999-01-28 | 2004-11-02 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
US6551778B1 (en) | 1999-01-28 | 2003-04-22 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2000044940A3 (en) * | 1999-01-28 | 2000-12-07 | Gen Probe Inc | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2000044940A2 (en) * | 1999-01-28 | 2000-08-03 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2004073657A3 (en) * | 2003-02-19 | 2005-04-21 | Protein Design Labs Inc | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
WO2004073657A2 (en) * | 2003-02-19 | 2004-09-02 | Protein Design Labs, Inc. | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
Also Published As
Publication number | Publication date |
---|---|
AU2676197A (en) | 1997-11-07 |
EP0904397A4 (en) | 2003-01-29 |
EP0904397A1 (en) | 1999-03-31 |
ZA973231B (en) | 1997-11-25 |
JP2000510331A (en) | 2000-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11104958B2 (en) | Method to detect prostate cancer in a sample | |
EP0667920B1 (en) | Methods of detecting micrometastasis of prostate cancer | |
JP4944041B2 (en) | Urinary sediment and / or urine mRNA ratio that is a prognostic marker and / or a terranostic marker for prostate cancer | |
US20090035773A1 (en) | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample | |
US20070020657A1 (en) | Methods for detecting circulating tumor cells | |
WO1994010343A9 (en) | Methods of detecting micrometastasis of prostate cancer | |
AU742753C (en) | Primers and methods for the detection of disseminated tumor cells | |
WO1998046788A9 (en) | Primers and methods for the detection of disseminated tumor cells | |
CN101466722A (en) | Methods for detecting mutations in JAK2 nucleic acid | |
JPWO2003060116A1 (en) | Nucleic acid detection method and system | |
EP0904397A1 (en) | A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer | |
US20090035774A1 (en) | Method for characterizing primary tumors | |
CA2251557A1 (en) | A method for detection of prostate specific antigen used in monitoring and diagnosis of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE GH HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997918724 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2251557 Country of ref document: CA Ref country code: CA Ref document number: 2251557 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997918724 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997918724 Country of ref document: EP |